---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-25-001693"
form_type: "8-K"
ticker: "XBIO"
cik: "0001534525"
company_name: "Xenetic Biosciences, Inc."
filed_at: "2025-03-19T23:59:59+00:00"
generated_at: "2026-05-24T11:42:18.158526+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Xenetic Biosciences FY2024 net loss $4.0M; cash $6.2M; advancing DNase I to IND

## Summary
- Net loss ~$4.0M for FY2024; R&D expenses fell 5.9% to $3.3M from $3.5M YoY.
- Royalty payments from Takeda sublicense ~$2.5M, relatively flat vs. prior year.
- Cash and cash equivalents at year-end ~$6.2M.
- Continuing DNase I development toward IND/Phase 1 for pancreatic carcinoma.
- Entered Clinical Trial Services Agreement with PeriNess for exploratory studies.

## SEC filing metadata
- accession: 0001683168-25-001693
- form_type: 8-K
- ticker: XBIO
- cik: 0001534525
- company_name: Xenetic Biosciences, Inc.
- filed_at: 2025-03-19T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534525/000168316825001693/0001683168-25-001693-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534525/000168316825001693/xenetic_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-25-001693
- JSON: https://secwatch.observer/filing/0001683168-25-001693.json
- Plain text: https://secwatch.observer/filing/0001683168-25-001693.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.